
Cipla obtains Formosa’ novel ophthalmic suspension multi-region marketing rights
New Delhi: Respiratory therapies and generic drug developer Cipla has secured multi-region marketing rights of Taiwan-based Formosa Pharmaceuticals Clobetasol Suspension APP13007 indicated for post-operative inflammation and pain following ocular surgery. …